Butterfly Network (NYSE: BFLY) director Erica Schwartz exits Board to lead CDC
Rhea-AI Filing Summary
Butterfly Network, Inc. reported that Dr. Erica Schwartz has resigned from its Board of Directors, effective automatically upon her confirmation as Director of the U.S. Centers for Disease Control and Prevention on August 5, 2026. The company states that her resignation does not result from any disagreement regarding operations, policies, or practices.
A press release dated August 11, 2026, attached as an exhibit, further notes that Dr. Schwartz had served on the Board since 2021 and stepped down in advance of assuming her new role at the CDC. Butterfly Network’s President, CEO and Chairman, Joseph DeVivo, is quoted recognizing her contributions and service to the company.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Effective resignation date: August 5, 2026
Press release date: August 11, 2026
Board service start year: 2021
+1 more
4 metrics
Effective resignation date
August 5, 2026
Date Dr. Erica Schwartz’s resignation from the Board became effective upon CDC confirmation
Press release date
August 11, 2026
Date of Exhibit 99.1 press release regarding Dr. Schwartz’s resignation and CDC role
Board service start year
2021
Year Butterfly states Dr. Erica Schwartz began serving on its Board of Directors
Telephone number
(781) 557-4800
Registrant’s telephone number listed for Butterfly Network’s principal executive offices
Key Terms
Emerging growth company, Inline XBRL, Centers for Disease Control and Prevention, Form 8-K, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
Centers for Disease Control and Prevention medical
"confirmation as Director of the Centers for Disease Control and Prevention by the U.S. Senate"
A national public health agency that tracks, investigates and issues guidance on infectious diseases, health threats and safety practices; it acts like a country's health early-warning and control center, coordinating labs, data and recommendations. Investors pay attention because its alerts, safety rules or study results can change consumer behavior, regulatory requirements or demand for medical products and services, affecting company sales, supply chains and stock prices.
Form 8-K regulatory
"Additional information regarding Dr. Schwartz's Board service and transition is included in a filed with the U.S. Securities and Exchange Commission."
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Ultrasound-on-Chip™ technical
"driving a digital revolution in ultrasound imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology"
Ultrasound-on-chip™ is a technology that puts the core parts of an ultrasound system — the sound transmitters, receivers and basic signal processing — onto a tiny semiconductor chip instead of separate bulky components. For investors it signals potential for much smaller, cheaper and power-efficient medical or sensing devices, which can expand markets, lower manufacturing costs and enable new products that reach more customers faster.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board change did Butterfly Network (BFLY) disclose on August 11, 2026?
Butterfly Network disclosed that Dr. Erica Schwartz resigned from its Board of Directors, effective August 5, 2026, following her confirmation as Director of the CDC by the U.S. Senate.
Why did Dr. Erica Schwartz resign from Butterfly Network (BFLY)’s Board?
Dr. Erica Schwartz resigned because she was confirmed as Director of the CDC on August 5, 2026. Butterfly Network states her resignation was not due to any disagreement with the company’s operations, policies, or practices.
When did Dr. Erica Schwartz’s resignation from Butterfly Network (BFLY)’s Board become effective?
Her resignation became automatically effective on August 5, 2026, the date she was confirmed by the U.S. Senate as Director of the CDC, as previously conditioned.
What exhibit accompanies Butterfly Network (BFLY)’s Form 8-K about Dr. Schwartz?
The filing includes Exhibit 99.1, a press release dated August 11, 2026 announcing Dr. Schwartz’s resignation and congratulating her on her confirmation as Director of the CDC.
Who signed Butterfly Network (BFLY)’s Form 8-K reporting Dr. Schwartz’s resignation?
The report was signed on behalf of Butterfly Network by John Doherty, Executive Vice President and Chief Financial Officer, dated August 11, 2026.